🚥 #leukemia #ASH21 🛎️ Last call for poster #️5️ 〰️ Graaph-2014 study ➕ adding Nelarabine to chemo for #ALL pts 🔹 #OncTwitter w/ @LoriMuffly & @LuskinMarlise 🔸#CME from @BonumCe 🔗bit.ly/3FIOane 🔸Supported by edu grant Jazz Pharma twitter.com/i/broadcasts/1…
2/🟠Get your 🆓 #CME
CME ℹ️👉 bit.ly/3FIOane
#MedTwitter #OncTwitter #leusm
✔️What are your credentials❓
3/ 🏆#CME credit provided by @IntegrityCE
🤝In partnership w/ @BonumCe
⏱️ Please answer! ⏱️
🟢 PRE-polls before 💬
🔴POST-polls after 💬
🟠or🔗 bit.ly/3FIOane for #CME ℹ️
👇CME info 👇
4/🟢PRE Poll 1️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic
🟢 Which of the following is best describes outcomes associated with addition of 1 cycle nelarabine in adults with ALL based on the UKALL14 study?
5/ 🟢PRE Poll 2️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic
🟢 An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCR𝛄deletion (ABD) were associated with which of the following outcomes?
6/🟢PRE Poll 3️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3FEdvic
🟢 Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of of first-line therapy on the GRAAPH 2014 protocol for Ph+ ALL is associated with:
7/ #ALL #BonumCE #ASH21
📝Omission of cytarabine was associated with 📈 risk of relapse in adults enrolled in the GRAAPH 2014 phase 3 RCT in Ph+ ALL
🧬28 patients had NGS at relapse
🧬71% of patients had a mutation identified
🧬50% of mutations identified involved T315I
8/ #ALL #BonumCE #ASH21
📝UKALL14 Phase 3 RCT adding 1 cycle of post-remission nelarabine in adult 👥 with newly diagnosed T-cell ALL
🙅🏽♂️No Δ in EFS or OS in 👥 receiving SOC compared with 👥 receiving SOC ➕ 1 cycle of nelarabine
👇
9/🔴POST Poll 1️⃣
#BonumCE #OncTwitter #MedTwitter
🟠#CME bit.ly/3sz5upH
🔴 Which of the following is best describes outcomes associated with addition of 1 cycle nelarabine in adults with ALL based on the UKALL14 study?
10/🔴POST Poll2️⃣
#BonumCE #OncTwitter
🟠#CME bit.ly/3sz5upH
🔴 An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCR𝛄deletion (ABD) were associated with which of the following outcomes?
11/🔴POST Poll 3️⃣
#MedTwitter #Webinar
🟠#CME bit.ly/3sz5upH
🔴 Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of of first-line therapy on the GRAAPH 2014 protocol for Ph+ ALL is associated with:
12/ ⚠️ Don’t forget to claim your 🆓 #CME @AmerMedicalAssn credit 🎫 bit.ly/3FIOane
Thank you for joining our #ALL #leukemia CME series w/ @BonumCe 💕
13/ 💁Need more ℹ️❓
🆓 Want more #CME ❓
#ICYMI 📽️ me, @RyanCassaday & Luke Maese, DO addressed asparaginase adherence, mgmt, & toxicities 🗓️
Catch our #ALL #leukemia #webinar here ⬇️
14/ Deeper dive? 🏊 Check out the rest of the poster series for more #ALL 📚 and #CME 🏆
🪧 1️⃣ - Results: Ph 2/3 recomb-ERW w @RyanCassaday & Luke Maese, DO @huntsmancancer
twitter.com/i/events/15299…
15/ #ICYMI #ALL 🪧 Poster 2️⃣ w @RyanCassaday & Luke Maese, DO @huntsmancancer review studies of #blinatumomab 💎AALL1331 @COGorg 💎Graall-2014-QUEST @NicBoissel
twitter.com/i/events/15299…
16/ #ICYMI #ALL 🪧 Poster 3️⃣: UKALL 2003 ➕10yr data GMALL 8/2013 of ND ALL/LBL with me and @LuskinMarlise
twitter.com/i/events/15367…
17/ #ICYMI #ALL 🪧 Poster 4️⃣: INITIAL-1 trial 🔹 EWALL-INO study 🔹 SWOG 1318 trial 🔹 #OncTwitter with @LuskinMarlise and me🔸#CME
twitter.com/i/events/15370…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.